Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.77 |
| ▸ | CCR2 | P41597 | 9/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CCR4 | P51679 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12040688 | 0.93 | CYP3A4 (0.80) | CYP2C9CCR2CYP3A4TNNI3KBRAF | |
| SCHEMBL12040687 | 0.87 | CYP3A4 (0.63) | CYP2C9CCR2CYP3A4TNNI3KBRAF | |
| SCHEMBL12040694 | 0.87 | CCR2 (0.62) | CYP2C9CCR2CYP3A4TNNI3KBRAF | |
| SCHEMBL12040691 | 0.87 | CYP2C9 (0.59) | CYP2C9CCR2CYP3A4TNNI3KBRAF | |
| SCHEMBL128785 | 0.87 | CYP2C9 (1.00) | CYP2C9CCR2CYP3A4 | |
| SCHEMBL1762314 | 0.86 | CYP2C9 (0.58) | CYP2C9CCR2CYP3A4TNNI3KBRAF | |
| SCHEMBL127931 | 0.86 | CCR2 (0.81) | CYP2C9CCR2CYP3A4TNNI3KBRAF | |
| SCHEMBL12040686 | 0.84 | CYP3A4 (0.72) | CYP2C9CCR2CYP3A4TNNI3KBRAF | |
| SCHEMBL12040684 | 0.84 | CYP2C9 (0.55) | CYP2C9CCR2CYP3A4MEN1LMNA | |
| SCHEMBL12040730 | 0.83 | CYP2C9 (0.54) | CYP2C9CCR2CYP3A4MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745312-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170022205-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-9394307-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-8546408-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110319433-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022205-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CYP2C9 1281/4885CCR2 1/4885CYP3A4 1134/4885 |
| US-20110319433-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CYP2C9 1281/4885CCR2 1/4885CYP3A4 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.